249 related articles for article (PubMed ID: 34408098)
21. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
Maloney DG; Liles TM; Czerwinski DK; Waldichuk C; Rosenberg J; Grillo-Lopez A; Levy R
Blood; 1994 Oct; 84(8):2457-66. PubMed ID: 7522629
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X
BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649
[TBL] [Abstract][Full Text] [Related]
24. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
Jensen MC; Popplewell L; Cooper LJ; DiGiusto D; Kalos M; Ostberg JR; Forman SJ
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1245-56. PubMed ID: 20304086
[TBL] [Abstract][Full Text] [Related]
25. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Makita S; Yoshimura K; Tobinai K
Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
[TBL] [Abstract][Full Text] [Related]
26. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.
Jensen M; Tan G; Forman S; Wu AM; Raubitschek A
Biol Blood Marrow Transplant; 1998; 4(2):75-83. PubMed ID: 9763110
[TBL] [Abstract][Full Text] [Related]
27. Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody.
Uhrik L; Hernychova L; Muller P; Kalathiya U; Lisowska MM; Kocikowski M; Parys M; Faktor J; Nekulova M; Nortcliffe C; Zatloukalova P; Ruetgen B; Fahraeus R; Ball KL; Argyle DJ; Vojtesek B; Hupp TR
Biochem J; 2021 Jan; 478(1):99-120. PubMed ID: 33284343
[TBL] [Abstract][Full Text] [Related]
28. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
29. Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential.
Ito D; Brewer S; Modiano JF; Beall MJ
Leuk Lymphoma; 2015 Jan; 56(1):219-25. PubMed ID: 24724777
[TBL] [Abstract][Full Text] [Related]
30. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
31. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment.
Mizuno T; Kato Y; Kaneko MK; Sakai Y; Shiga T; Kato M; Tsukui T; Takemoto H; Tokimasa A; Baba K; Nemoto Y; Sakai O; Igase M
Sci Rep; 2020 Jul; 10(1):11476. PubMed ID: 32651429
[TBL] [Abstract][Full Text] [Related]
32. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
33. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
34. Canine CD20 gene.
Kano R; Inoiue C; Okano H; Yamazaki J; Takahashi T; Watari T; Tokuriki M; Hasegawa A
Vet Immunol Immunopathol; 2005 Dec; 108(3-4):265-8. PubMed ID: 16061290
[TBL] [Abstract][Full Text] [Related]
35. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
James SE; Orgun NN; Tedder TF; Shlomchik MJ; Jensen MC; Lin Y; Greenberg PD; Press OW
Blood; 2009 Dec; 114(27):5454-63. PubMed ID: 19880489
[TBL] [Abstract][Full Text] [Related]
36. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
38. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
40. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]